Development and validation of an interpretable machine learning model for predicting 5-year recurrence in breast cancer
-
By
-
Shaoda Meng
-
Sicheng Liu
-
Minghua Lai
-
Li Li
-
June 10, 2026
-
Clinical Report: Creation and assessment of a transparent machine learning model for forecasting 5-year breast cancer recurrence
Overview
{'add': 'Specify metrics for accuracy comparison.'}
Background
{'add': 'Include statistics on recurrence rates.'}
Data Highlights
{'format': 'Ensure table format is clear.'}
Key Findings
{'add': 'Include significance details for findings.'}
Clinical Implications
{'add': 'Discuss model limitations.'}
Conclusion
{'add': 'Emphasize impact on patient outcomes.'}
Related Resources & Content
- Author(s)/Org, Source, Year -- Title
- Author(s)/Org, Source, Year -- Title
- Author(s)/Org, Source, Year -- Title
- Author(s)/Org, Source, Year -- Title
- NCCN Guidelines® Insights: Breast Cancer, Version 5.2025 - PubMed
- Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update | Journal of Clinical Oncology
- Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment | Eli Lilly and Company
- 21-Gene Recurrence Score and Survival Outcomes in the Phase III Multicenter TAILORx Clinical Trial - PubMed
- RxPONDER Update Explores Benefit of Chemotherapy in Subgroups - The ASCO Post
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update | Journal of Clinical Oncology
- Long‐Term MINDACT Results Affirm Excellent Prognosis for Clinically and Genetically Low‐Risk Early Breast Cancer - PMC
- Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update | Journal of Clinical Oncology
- Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy - PMC
- Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer | New England Journal of Medicine
- Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer - PMC
- Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials - PubMed
